Sign in
WithdrawnPhase 1/2

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Key facts

Who runs it
Fred Hutchinson Cancer Center
Where
Seattle, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
1 Apr 2025
Expected to end
30 Oct 2027
Type of study
Interventional
Treatments tested
  • Interferon Beta-1A
  • X-Ray Imaging
  • Echocardiography
  • Multigated Acquisition Scan
  • Computed Tomography
  • Positron Emission Tomography
  • Lumbar Puncture
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Biospecimen Collection
  • Biopsy
Record updated
12 July 2024
Why it stopped
Study closed before opening to accrual, no participants enrolled

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Participants must be 18 years of age or older
  • Karnofsky performance status of >= 60%
  • Participants eligible for treatment with axi-cel or brexu-cel
  • Negative serum pregnancy test within 2 weeks of enrollment for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
  • Fertile male and female participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last dose of FP-1201
  • Ability to understand and provide informed consent

Who cannot take part

  • Corticosteroid use (> 20mg/day of prednisone, or equivalent) within 7 days prior to first FP-1201 administration
  • Uncontrolled serious and active infection
  • Known hypersensitivity to natural or recombinant interferon beta, albumin or any other component of the formulation
  • Estimated creatinine clearance (Cockcroft and Gault) =< 60 mL/min
  • Severe hepatic dysfunction defined as group C of the National Cancer Institute Organ Dysfunction Working Group hepatic impairment criteria (total bilirubin > 3x upper limit of normal [ULN] with any aspartate aminotransferase [AST] or alanine transaminase [AL]T value), or AST or ALT > 3x ULN, unless due to malignancy or Gilbert's syndrome in the opinion of the principal investigator (PI) or designee
  • Significant cardiovascular abnormalities as defined by any one of the following:; New York Heart Association (NYHA) class III or IV congestive heart failure, clinically significant hypotension; Uncontrolled symptomatic coronary artery disease, or a documented ejection fraction of < 35%
  • Significant proteinuria defined as 2+ or 3+ proteinuria or urinary protein >= 1g/24h
  • Participants with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing, as clinically indicated. Those with an forced expiratory volume in the first second (FEV1) of < 50 % of predicted or diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected) < 40% will be excluded

Where in United States

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, United States

About the trial

What the trial wants to find out

This phase I/II trial tests the safety and how well intravenous interferon-beta-1a (FP-1201) works in preventing toxicities after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell cancers that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Interferon beta-1a is in a class of medications called immunomodulators. It works by protecting the lining of blood vessels, and preventing brain inflammation. Giving FP-1201 may prevent cytokine release syndrome (CRS) and immune effector cell associated-neurotoxicity syndrome (ICANS) toxicities in patients receiving CD19 CAR T-cell therapy with recurrent or refractory B-cell malignancies.

The group in the trial

  • Prevention (interferon beta-1A [FP-1201])Treatment being tested

    Patients undergo leukapheresis prior to treatment and receive FP-1201 IV for 3 days every 24 hours from day -3 through day -1 or for 5 days every 24 hours from day -5 through day -1 or on day -5, day -3, and day -1. Patients may receive lymphodepletion chemotherapy with either cyclophosphamide IV and fludarabine IV on days -5, -4, -3 followed by axi-cel IV or brexu-cel IV on day 0 or fludarabine IV over 30 minutes on days -4, -3, and -2 and cyclophosphamide IV over 60 minutes on day -2 followed by brexu-cel IV on day 0. Patients undergo x-ray imaging and ECHO or MUGA during screening. Patients also undergo CT or PET/CT as well as LP for CSF collection and/or bone marrow aspiration and biopsy as clinically indicated during screening and follow-up. Patients undergo blood sample collection on study and during follow-up as well as a tissue biopsy during screening and follow-up.

    Treatment: Interferon Beta-1A, X-Ray Imaging, Echocardiography, Multigated Acquisition Scan, Computed Tomography, Positron Emission Tomography, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, and Biopsy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Record updated
12 July 2024